Manassas, VA, September 20, 2022 –(PR.com)– The National Cancer Institute awarded Serpin Pharma a $400,000 competitive R43 grant for the Pre-clinical validation of phase II peptide LRP-1 agonist to treat and prevent chemotherapy-induced peripheral neuropathy.

The Principal Investigators are Serpin Pharma’s CEO and Executive Chairperson, Dr. Cohava Gelber and collaborator, Dr. Wendy Campana, Professor of Anesthesiology and Program in Neuroscience at the University of California, San Diego.

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequently experienced adverse side effect of patients receiving cancer treatments. Peripheral Neuropathy is the result of damage to the peripheral nerves and is associated with tingling, numbness, weakness, and pain, typically occurring in the hands and feet. Because of the chronic pain and other symptoms associated with CIPN, effective doses of chemotherapeutic agents are…